Poster Information

 

PRESENT A POSTER AND SAVE $50!
   DEADLINE EXTENDED TO APRIL 11 
 

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure a poster board and inclusion in the conference materials, your abstract must be submitted, approved and your registration paid in full by April 11, 2014. 

Register online, or by phone, fax or mail.   

For this conference, if you would like to present a poster, please email your abstract directly to jring@healthtech.com and include the poster title, authors, affiliations, abstract text and presenter name.  (The poster discount will be applied upon approval.) 

Reasons you should present your research poster at this conference: 

  • Your poster will be exposed to our international delegation 
  • Receive $50 off your registration 
  • Your poster abstract will be published in our conference materials 
  • Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes 


Note: Posters should be portrait orientation, with maximum dimensions of
36 inches wide (3 feet) x 48 inches high (4 feet).
 


Click here for poster instructions
 


 2014 Posters (Partial List) 

  • 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs
  • A Fast and Reliable Empirical Approach for Estimating Solubility of Crystalline Drugs in Polymers for Hot Melt Extrusion Formulations
  • A photochemical method for determining plasma homocysteine with limited sample processing
  • A Theranostic Approach to the Prevention and Imaging of Intraperitoneal Adhesions using a Drug Loaded Nano-Sized Liposomal Formulation
  • A2A adenosine receptor gene-deletion or selective antagonism liberates anti-tumor CD8+ T cells from tumor-induced immunosuppression.
  • An Engineered Inert matrix to study Cancer stem cells properties in vitro
  • Assaying protease activity using enzyme-activatable optical probes in tumors subjected to photodynamic therapy
  • BRAF[V600E] Melanoma PDX Models and Isogenic Cell Lines Reveal Diverse BRAFi Resistance Mechanisms Overcome by Rationale Drug Design Including Treatment with MEKi Through Tumor Progression
  • Carbonic anhydrase and Hsp90 inhibitors as potential anticancer agents
  • Case Review for Multi-Targeted Epigenetic Therapy (MTET) and Its Rationale in an Integrative Approach
  • Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers
  • Challenges in the Crystallisation Development of a Highly Solvated Drug Substance.
  • Chronic and Analgesic-Reversible Depression of Motivated Behavior in Rats by Formalin but not by Complete Freund’s Adjuvant: Implications for Models of Chronic Pain
  • Clinical Presentation and Treatment Pattern of Breast Cancer: A Single Centre Study
  • Coupling chemical images of dry powder inhalation formulation structure to formulation performance
  • Design and optimization of curcumin loaded polymeric nanocapsules for colonic pathologies
  • Development of a Large Animal Model to Evaluate CAR T-cell Therapy: Ex vivo Activation, Expansion, and Genetic Modification of Canine T-cells
  • Engineering Substrate-Independent Autobioluminescence for Preclinical Drug Safety Evaluation: From Human Cell Lines to Zebrafish
  • Histopathological Evaluation of Nephroprotective Effect of Trichosanthes dioica Roxb. on Gentamicin Induced Nephrotoxicity in Wistar Rats by Colorimetry and Spectrophotometry
  • Importance of a dynamical environment for Heart Valve Tissue Engineering
  • Improvement of Mitochondrial Function by Paliperidone Attenuates Quinolinic Acid Induced Neuroinflammation and Apoptosis in Rats: Implications in Huntington’s Disease
  • In Silico Structure Prediction and Validation of GPCRS via Threading based homology modeling
  • In vivo imaging of orthotopic neuroblastoma PDXs
  • Innovative Nanostructured PEDOT-CNT Electrodes Enhance Conventional and Multiwell Microelectrode Recording from iPS Cell Derived Cardiomyocytes
  • In-silico study of probable cancer preventive herbal compounds
  • Label-Free HTS of Ion Transporters and Ion Channels
  • Low brain penetrant cannabinoid receptor agonists for the treatment of cisplatin induced peripheral neuropathy.
  • Lung Cancer: New information from Old Data
  • Mapping CB1 Allosteric Sites for Developing Safer and Effective Anti-obesity Pharmacotherapy
  • miR-130b promotes Ewing's Sarcoma metastasis through Cdc42 activation
  • Modeling Human Neuroblastoma in mice
  • Multiple-Pathway Tracer Kinetic Models of Blood Flow: Issues with a discrete number of pathways
  • Oral Delivery of FimH Antagonists
  • Selecting improved affinity AFP-specific T Cell Receptors for hepatocellular carcinoma
  • Small Molecule HIF2a Inhibitors Suppress VHL Phenotype In Vivo
  • Solid Lipid Nanoparticles of Levamisole Hydrochloride
  • Species specific sequencing of the subpopulations within tumor models of breast cancer
  • Study of the interaction of synthetic food azo dyes with medicinal substances
  • Tangeretin Enhances the Therapeutic Effect of 5-Fu Against Colon Cancer In Vivo and In Vitro by Inhibiting miR-21 at Low Concentration
  • Targeting glioblastoma and lung carcinoma via intranasal delivery of Ff bacteriophages
  • Temporal expression and promoter region methylation of c-myc during normal and pathological pregnancies
  • The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment
  • The prospects for Personalized Medicine in preclinical drug development
  • Treatment of Urinary Tract Infections - Optimized Drug Delivery of FimH Antagonists
  • Use of peptide saturation mutagenesis to optimise and characterise T cell receptors for adoptive T cell therapy of cancer
  • Variations analysed by BarCoding analysis